相关实验视频
Updated: May 28, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.6K
发现和优化Pyrazine Carboxamide AZ3246,一种选择性HPK1抑制剂的发现和优化
Jason D Shields1, David Baker2, Amber Y S Balazs1
1Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Journal of medicinal chemistry
|February 10, 2025
概括
研究人员开发了一种选择性抑制剂,用于血液生成原体激酶1 (HPK1),这是癌症免疫治疗的关键标. 这种新化合物增强T细胞活性,并在临床前模型中显示出有前途的抗瘤作用.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 造血原体激酶1 (HPK1) 负面调节T细胞受体信号传递.
- 非选择性HPK1抑制剂可能会对T细胞激活产生非目标效应.
- 向HPK1是一种在免疫瘤学中增强抗瘤免疫力的策略.
研究的目的:
- 发现和优化选择性HPK1抑制剂.
- 开发一种可以增强T细胞活性而不会抑制其他激酶的化合物.
- 评估一种新型选择性HPK1抑制剂的治疗潜力.
主要方法:
- 基于结构的药物设计被用来优化pyrazine carboxamide 抑制剂.
- 合成并描述了化合物24 (AZ3246) 的特征.
- 在体外测定测量IL-2分泌和激酶抑制. 在体内研究评估了合成基因小鼠模型中的药理动力学特性和抗瘤活性.
主要成果:
- 确定了一种高度选择性的HPK1抑制剂,化合物24 (AZ3246).
- 化合物24诱导T细胞中的IL-2分泌,EC50为90nM.
- 该化合物在EMT6模型中显示了口服时有利的药理动力学和显著的抗瘤活性.
结论:
- 选择性抑制HPK1是可以实现的,并且具有治疗意义.
- 化合物24是免疫瘤学治疗的有希望的候选者.
- 这种选择性抑制剂增强T细胞功能,并表现出抗瘤功效.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.1K
相关概念视频
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K